tradingkey.logo
tradingkey.logo

Elevar Therapeutics Announces FDA Acceptance For Review Of New Drug Application For Lirafugratinib

ReutersMar 30, 2026 12:04 PM

-

  • ELEVAR THERAPEUTICS ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR LIRAFUGRATINIB AS SECOND-LINE CHOLANGIOCARCINOMA TREATMENT

  • ELEVAR THERAPEUTICS: FDA GRANTED PRIORITY REVIEW, WITH A PDUFA TARGET ACTION DATE OF SEPTEMBER 27, 2026

Further company coverage: [ ]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI